STOCKHOLM, Sweden, March 14, 2001 (PRIMEZONE) -- Elekta (SSE:EKTAB) has recently swept the board with an award for 100% of the orders in the recent wave of Linear Accelerators funded from the New Opportunities Fund (NOF). This order for the United Kingdom National Health Service is the latest round of orders in a major program for cancer prevention, detection, treatment and care which includes breast screening equipment, MRI machines as well as Linear Accelerators. With the latest 6 systems, Elekta has now won more orders from the NOF program than all the other suppliers combined, confirming its leadership status in the UK.
Another significant contract has recently been signed with Zwolle, the Netherlands, for three Precise Treatment Systems, all with MLC and iViewGT. The addition of PreciseSIM simulator and network integration completes the full package which delivers enhanced process efficiency.
ELEKTA is a world-leading supplier of radiation oncology and radiosurgery solutions for precision radiotherapy and neurosurgery. Elekta Precise Solutions(tm) includes a comprehensive range of non-invasive cancer care and minimally invasive neurosurgery systems including radiosurgery and stereotaxy, backed by a global network of clinical, technical, and financial support services. Radiotherapy products include Elekta Precise Treatment System utilizing digital technology in linear accelerators and multi-leaf collimators, PreciseSIMTM treatment simulator, Stereotactic Body Frame(r), and conformal 3-D dose-planning systems. Neurosurgery products include Leksell Gamma Knife(r) and Leksell Stereotactic System(r) .
...providing Precise Solutions